Zunsemetinib
Small moleculeexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Mar 2, 2020 (NCT04247815)
Timeline
Indications
Mechanism of action
MAPKAPK2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cnc(-c2ccnc(C(C)(C)O)n2)cc1-n1c(C)cc(OCc2ncc(F)cc2F)c(Cl)c1=O- Mol. weight
- 513.93 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3704901 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06648434 | Phase 1 | Dec 31, 2024 | Aclaris Therapeutics, Inc., National Cancer Institute (NCI), Washington University in St. Louis |
| NCT06374459 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2024 | Aclaris Therapeutics, Inc., Department of Defense, Washington University in St. Louis |
| NCT05511519 | Phase 2 | Jul 12, 2022 | Aclaris Therapeutics, Inc. |
| NCT05279417 | Phase 2 | Feb 2, 2022 | Aclaris Therapeutics, Inc. |
| NCT05216224 | Phase 2 | Dec 29, 2021 | Aclaris Therapeutics, Inc. |
| NCT04524858 | Phase 2 | Oct 23, 2020 | Aclaris Therapeutics, Inc. |
| NCT04481685 | Phase 2 | Jul 20, 2020 | University of Kansas |
| NCT04247815 | Phase 2 | Mar 2, 2020 | Aclaris Therapeutics, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | For profit | 7 | 5 | 2 | 2020 |
| Washington University in St. Louis | Academic/Hospital | 2 | 2 | 2 | 2024 |
| Department of Defense | Government | 1 | 0 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2024 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1